Deep Apple and Novo Nordisk Partner on Cardiometabolic Drug Discovery

June 13, 2025
Deep Apple Therapeutics has announced a collaboration with Novo Nordisk to develop oral therapeutics for cardiometabolic diseases, potentially earning up to $812 million.

Deep Apple Therapeutics has announced a collaboration with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases, including obesity. Announced in a press release, the partnership aims to create first-in-class small molecule therapeutics targeting a novel non-incretin GPCR.

Under the agreement, Deep Apple will utilize its proprietary drug discovery platform, which integrates machine learning and cryo-electron microscopy, to identify and optimize compounds. Novo Nordisk will have exclusive global rights to develop, manufacture, and commercialize the resulting products.

Deep Apple is eligible to receive up to $812 million, including an upfront payment, research costs, and milestone payments, along with potential royalties on future sales. The collaboration will see both companies working together on the research plan, with Novo Nordisk taking over before the start of IND-enabling studies.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

07/29
Arbital Health Secures $31M to Expand AI-Powered Healthcare Platform
07/29
Proprio Joins AWS Partner Network to Enhance Surgical AI Platform
07/29
Briya Launches AI Platform for Medical Research
07/29
Johnson & Johnson Introduces AI-Powered VIRTUGUIDE System for Bunion Surgery
07/29
Machine Learning Model Predicts No-Shows in Primary Care

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Governing the Future: A Strategic Framework for AI Adoption in Financial Institutions

This whitepaper explores the transformative impact of artificial intelligence on the financial industry, focusing on the governance challenges and regulatory demands faced by banks. It provides a strategic framework for AI adoption, emphasizing the importance of a unified AI approach to streamline compliance and reduce operational costs. The document offers actionable insights and expert recommendations for banks with fewer than 2,000 employees to become leaders in compliant, customer-centric AI.

Read more

You May Also Like